Nautilus Biotechnology News

Morgan Stanley Reiterates Equal-Weight on Nautilus Biotechnology, Maintains $6 Price Target

BenzingaAug 3, 2023 11:22 ET

Nautilus Biotechnology Analyst Ratings

BenzingaAug 3, 2023 11:21 ET

Goldman Sachs Halves Price Target on Nautilus Biotechnology to $2 From $4 Amid Product Launch Delay; Neutral Rating Kept

MT NewswiresAug 4, 2022 06:41 ET

Morgan Stanley Lowers Nautilus Biotechnology's Price Target to $6 From $8, Maintains Equalweight Rating

MT NewswiresAug 3, 2022 10:38 ET

Nautilus Biotechnolgy Price Target Cut to $6.00/Share From $8.00 by Morgan Stanley

Dow JonesAug 3, 2022 10:10 ET

Nautilus Biotechnolgy Is Maintained at Equal-Weight by Morgan Stanley

Dow JonesAug 3, 2022 10:10 ET

Morgan Stanley Maintains Equal-Weight on Nautilus Biotechnology, Lowers Price Target to $6

Benzinga Real-time NewsAug 3, 2022 10:00 ET

Nautilus Biotechnolgy Is Maintained at Neutral by Goldman Sachs

Dow JonesAug 3, 2022 09:30 ET

Nautilus Biotechnolgy Price Target Cut to $2.00/Share From $4.00 by Goldman Sachs

Dow JonesAug 3, 2022 09:30 ET

Nautilus Biotechnology analyst ratings

Benzinga Analyst RatingsAug 3, 2022 09:20 ET

Goldman Sachs Maintains Neutral on Nautilus Biotechnology, Lowers Price Target to $2

Benzinga Real-time NewsAug 3, 2022 09:20 ET

Goldman Sachs Adjusts Nautilus Biotechnology's Price Target to $4 from $5, Keeps Neutral Rating

MT NewswiresJul 14, 2022 12:35 ET

Nautilus Biotechnolgy Price Target Cut to $4.00/Share From $5.00 by Goldman Sachs

Dow JonesJul 14, 2022 11:48 ET

Nautilus Biotechnolgy Is Maintained at Neutral by Goldman Sachs

Dow JonesJul 14, 2022 11:48 ET

Nautilus Biotechnology analyst ratings

Benzinga Analyst RatingsJul 14, 2022 11:38 ET

Goldman Sachs Maintains Neutral on Nautilus Biotechnology, Lowers Price Target to $4

Benzinga Real-time NewsJul 14, 2022 11:38 ET